BRII BIOSCIENCES
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.
BRII BIOSCIENCES
Social Links:
Industry:
Biotechnology Health Care Innovation Management Pharmaceutical
Founded:
2018-01-01
Status:
Active
Email Addresses:
[email protected]
Total Funding:
415 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Domain Not Resolving Apache Global Site Tag
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Enveda Biosciences
Enveda Biosciences is a biotechnology company building new medicines from plants.
EQRx
EQRx is a biotechnology company that focuses on re-engineering the process of drug discovery to make them affordable.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Inovio Pharmaceuticals
Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Invesco
Invesco investment in Series C - Brii Biosciences
Proioxis Ventures Fund
Proioxis Ventures Fund investment in Series C - Brii Biosciences
GIC
GIC investment in Series C - Brii Biosciences
Lake Bleu Capital
Lake Bleu Capital investment in Series C - Brii Biosciences
ARCH Venture Partners
ARCH Venture Partners investment in Venture Round - Brii Biosciences
6 Dimensions Capital
6 Dimensions Capital investment in Venture Round - Brii Biosciences
Sequoia Capital China
Sequoia Capital China investment in Venture Round - Brii Biosciences
Blue Pool Capital
Blue Pool Capital investment in Venture Round - Brii Biosciences
YF Capital
YF Capital investment in Venture Round - Brii Biosciences
Boyu Capital
Boyu Capital investment in Venture Round - Brii Biosciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-11-21 | AN2 Therapeutics | Brii Biosciences investment in Series A - AN2 Therapeutics | 12 M USD |
| 2019-06-11 | Artizan Biosciences | Brii Biosciences investment in Series A - Artizan Biosciences | 12 M USD |
Key Employee Changes
More informations about "Brii Biosciences"
About Us | Brii Biosciences
Brii Biosciences is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas.See details»
Press Release | Brii Biosciences
Nov 19, 2024 · Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients …See details»
Home | Brii Biosciences
Nov 19, 2024 · Brii Biosciences is a biotechnology company developing therapies to address some of the world’s most common public health challenges where patients experience high …See details»
Brii Biosciences - LinkedIn
Brii Biosciences is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant...See details»
Brii Biosciences - Crunchbase Investor Profile & Investments
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's …See details»
Brii Biosciences Provides Latest Clinical Development and …
Jul 5, 2023 · DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited (" Brii Bio " or the "Company", stock code: 2137.HK), a biotechnology company developing …See details»
Brii Biosciences Announces Two Breakthrough Therapy …
May 13, 2024 · Brii Biosciences Limited (" Brii Bio ", stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients …See details»
Brii Biosciences Closes US$155 Million Series C Financing
Mar 23, 2021 · DURHAM, N.C. & BEIJING-- ( BUSINESS WIRE )--Brii Biosciences (“Brii Bio”), a multi-national company developing innovative therapies for diseases with significant unmet …See details»
VBI Vaccines and Brii Biosciences Expand Hepatitis B …
Jul 5, 2023 · Through two license and collaboration agreements, Brii Bio expanded its exclusive license to VBI-2601 (BRII-179), VBI’s HBV immunotherapeutic candidate, to global rights and …See details»
Brii Biosciences Announces Two Breakthrough Therapy …
May 13, 2024 · This represents another milestone in the Company's pursuit of a functional cure for HBV, following the Breakthrough Therapy Designation granted for BRII-179, a recombinant …See details»
Leadership | Brii Biosciences
Brii Biosciences is a biotechnology company developing therapies to address some of the world’s most common public health challenges where patients experience high unmet medical needs, …See details»
China’s Brii Bio Raises $319 million in the Hong Kong IPO
China’s Brii Biosciences has raised $319 million in the initial public offering (IPO) in HKEX. The company announced that the proceeds would be used to support the development of its …See details»
Brii Biosciences - Funding, Financials, Valuation
Brii Biosciences is a biotechnology company that commits to bring innovative medicines to China as a way to improve public health.See details»
Brii Biosciences, Vir Biotechnology, and VBI Vaccines …
Apr 21, 2021 · Brii Bio has led the design and implementation of this functional cure proof-of-concept study with the support of VIR and VBI, and is the sponsor of the Phase 2 study …See details»
Brii Biosciences Provides Corporate Update and Reports …
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high …See details»
VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a …
Nov 14, 2019 · BRII-179 (VBI-2601) is uniquely formulated to target both B-cell and T-cell immunity through multiple mechanisms of action, including neutralizing the circulating hepatitis …See details»
Press Release | Brii Biosciences
Nov 14, 2023 · New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg loss or HBV functional cure rates. New data support …See details»
China approves Brii Biosciences antibody COVID treatment
Dec 8, 2021 · China's medical products regulator said on Wednesday it had approved the use of Brii Biosciences' neutralising antibody cocktail for COVID-19, the first treatment of its type …See details»
Brii Biosciences halts manufacture of COVID-19 antibody …
Mar 24, 2023 · By choosing antibodies from the plasma of a wide range of recovered COVID-19 patients, Brii Biosciences hoped to score big with a treatment that would stand up to …See details»
VBI Vaccines Partner Brii Biosciences Announces Topline …
BRII-179 (VBI-2601) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine …See details»